ArticleAdvances in therapy2023

The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China.

Rihua Cheng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.